ClinicalTrials.gg

Program

HS-10542

A development code. Also written as “HS-10542 High Dose” and “HS-10542 Low Dose”.

In Hansoh Pharmaceutical Group's pipeline, factor B. Its studies are mostly in Hemoglobinuria, Paroxysmal · Glomerulonephritis, IGA, led by Hansoh Pharmaceutical Group.

Furthest: phase 2, since Jan 26, 20263 company-led studies, 3 open or runningNext primary completion: May 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group33 open or runningphase 2since Jan 26, 2026May 8, 2025May 30, 2027phase 2 · NCT07470762
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-10542 (factor B), phase 2, as of Aug 26, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 8, 2025First study: phase 1 study in HealthyFirst studyNCT07040046 · 100 planned · China
  2. Jan 26, 2026Phase 2 study in Hemoglobinuria, ParoxysmalPhase 2 reachedNCT07470762 · 50 planned · China
  3. Feb 26, 2026Phase 2 study in Glomerulonephritis, IGANCT07474636 · 90 planned · China

Ahead

  1. May 30, 2027Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT07470762
  2. Dec 10, 2027Primary completion: phase 2 study in Glomerulonephritis, IGANCT07474636

TargetBeta

“factor B”the company's pipeline, read by Claude · source

Other programs on CFB

ProgramCompanyFurthest phaseStudies
iptacopanruleNovartisphase 325
HRS-5965Jiangsu HengRui Medicinephase 314
NTQ5082ruleSino Biopharmaceuticalphase 36
FXS6837Fosun Pharmaphase 34
sefaxersenHoffmann-La Rochephase 31
FWY003Novartisphase 21
SAR446597Sanofiphase 21

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07474636Glomerulonephritis, IGA · China2Not yet recruitingDec 10, 202790
NCT07470762Hemoglobinuria, Paroxysmal · China2RecruitingMay 30, 202750
NCT07040046Healthy · China1RecruitingDec 4, 2025100

How it is read

Names in the registry

  • “HS-10542”, 5 entries
  • “HS-10542 High Dose”, 1 entry
  • “HS-10542 Low Dose”, 1 entry

Codes read as this program: HS10542.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.